MicroPort commences local commercial operations in Telangana, with the World’s innovative technology Target Eluting Stent (TES) for coronary arteries

Veröffentlicht von: Helen Tan
Veröffentlicht am: 30.10.2017 13:23
Rubrik: Gesundheit & Medizin

(Presseportal openBroadcast) - MicroPort’s innovative 3rd generation technology, Target Eluting Stent (TES): FIREHAWK that helps coronary arteries of patients heal faster with fewer polymers & less drug load, post angioplasty has made its spectacular entry to India. It ensures a low risk of re-blockage (restenosis) and blood clotting (thrombosis). Now, these Stents are available in India and have been approved in more than 65 hospitals including some premier government and private hospitals in the country.

So far interventional cardiologists have been using Bare Metal Stents (BMS) or Drug Eluting Stents (DES) in patients but the availability of Target Eluting Stent (TES) now adds to their choice of stent selection for better patient care. Interventional cardiologists all over the world are all praises for Target Eluting Stent (TES) that is designed for high quality patient care, faster recovery and less long term complications.

Mr. Riyaz Desai, the Managing Director, MicroPort India, that manufactures such stents discussed with media during his visit to Hyderabad, “Cardiovascular diseases, especially Coronary Heart Disease (CHD), in India is an epidemic. According to the report by the Registrar General of India, CHD led to 17% of total deaths and 26% of adult deaths in 2001-2003, which increased to 23% of total and 32% of adult deaths in 2010-2013. The rapidly growing youth and adult cases of CHD in India beckon for the best quality healthcare products and services.

Citing successful clinical trials, Dr. Martin Leon of USA at a recently held Euro PCR 2017 conference (Paris Course of Re-vascularization) highlighted the influence of “Low TLR rates and significantly low Def/Prob Stent Thrombosis (ARC defined) with FireHawk in TARGET Clinical trials.” At the same symposium in Paris, Dr. William Wijns from Europe also shared 3 months OCT follow-up data of “TARGET ALL Comers” European trial and noted faster healing of coronary arteries treated by Firehawk: Target Eluting Stent.

“We are very pleased to bring TES to Telangana within 7 months of commencement of our Indian operations. FIREHAWK, the Target Eluting Stent is approved in more than 26 countries for sale and is one of the most premium stents in the market. FIREHAWK is truly a generation beyond Drug Eluting Stent (DES) because of its innovative stent design with low load of bioabsorbable polymer and drug that is released only towards the vessel walls ( smooth muscle cells),” adds Mr. Desai.

The proprietary advanced Robotic laser cut & 3D printing technology used in TES creates small grooves on the surface of the stent strut facing the vessel wall. In these grooves, the drug and bio-absorbable polymer is impregnated. Target Eluting Stent offers optimal and faster healing, leading to less chances of re-blockage and stent related blood clot formation (thrombosis) as seen in TARGET clinical trials.

Millions of lives are improved worldwide through modern innovations and technologies which are gradually cascading in the Indian market. MicroPort’s entry into the Indian market coincides with the recent price regulation; however MicroPort continues to penetrate all regions in India and not just metros. By now FireHawk is approved for sale in more than 65 leading hospitals in India. Commencement of operations in Telangana is an example of MicroPort’s commitment to make its world class technologies accessible to all in India.

About MicroPort® MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology. For more information, please refer www.microportindia.com

MicroPort Scientific India Pvt. Ltd.
801, 215 Atrium II, Behind Courtyard Marriott
Andheri Kurla Road, Andheri (East)
Mumbai 400059
Ph: +91-22-71912900

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.